What is Anika Therapeutics, Inc. worth?
With the base-case assumptions below, a discounted cash flow model on Anika Therapeutics, Inc.'s reported free cash flow gives $6.17 per share. The share price was $20.37 on September 25, 2026, 230% above that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | -8.0% | 10.0% | $4.88 | -76% |
| Base | -3.0% | 9.0% | $6.17 | -70% |
| Bull | 2.0% | 8.0% | $8.57 | -58% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $7.04 | $7.30 | $7.61 | $8.01 | $8.51 |
| 8.0% | $6.39 | $6.56 | $6.76 | $7.00 | $7.29 |
| 9.0% | $5.92 | $6.03 | $6.17 | $6.32 | $6.50 |
| 10.0% | $5.56 | $5.64 | $5.73 | $5.84 | $5.96 |
| 11.0% | $5.27 | $5.33 | $5.39 | $5.47 | $5.56 |
Where the presets come from
Base: years 1 to 5 grow at Anika Therapeutics, Inc.'s revenue growth rate over the last 5 fiscal years (-2.9% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions